Cancer : (Record no. 26776)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11107nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6561640 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724115052.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2020 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781975149130 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781975149116 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6561640 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6561640 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1247675150 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC268.4 .C363 2021 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.994 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | DeVita, Vincent T. |
| 245 10 - TITLE STATEMENT | |
| Title | Cancer : |
| Remainder of title | Principles and Practice of Oncology Primer of Molecular Biology in Cancer. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 3rd ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Philadelphia : |
| Name of producer, publisher, distributor, manufacturer | Wolters Kluwer Health, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2020. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2020. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1011 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Contributors -- PART I: Principles of Molecular Oncology -- 1. The Cancer Genome -- Yardena Samuels, Alberto Bardelli, Yochai Wolf, and Carlos López-Otin -- Introduction -- Cancer Genes and Their Mutations -- Identification of Cancer Genes -- Cancer Gene Discovery by Sequencing Candidate Gene Families -- Mutational Analysis of Exomes Using Sanger Sequencing -- Next-Generation Sequencing and Cancer Genome Analysis -- Whole-Genome Analysis Utilizing Second-Generation Sequencing -- Whole-Exome Analysis Utilizing Second-Generation Sequencing -- Somatic Alteration Classes Detected by Cancer Genome Analysis -- Pathway-Oriented Models of Cancer Genome Analysis -- Passenger and Driver Mutations -- Networks of Cancer Genome Projects -- The Genomic Landscape of Cancers -- Single-Cell Genomics -- Integrative Analysis of Cancer Genomics -- Immunogenomics -- The Cancer Genome and the New Taxonomy of Tumors -- Liquid Biopsies as a Diagnosis Tool -- Clinical Applications of Liquid Biopsies -- Cancer Genomics and Drug Resistance -- Perspectives of Cancer Genome Analysis -- Acknowledgments -- 2. Molecular Methods in Cancer -- Larissa V. Furtado, Jay L. Hess, and Bryan L. Betz -- Applications of Molecular Diagnostics in Oncology -- Biomarker Genetics -- Use of Biomarkers in Diagnosis -- Use of Biomarkers in Prognosis -- Use of Biomarkers in Predicting Response to Therapy -- Use of Biomarkers in Therapeutic Disease Monitoring -- Use of Biomarkers in Risk Assessment and Cancer Prevention -- The Clinical Molecular Diagnostics Laboratory: Rules and Regulations -- Specimen Requirements for Molecular Diagnostics -- Molecular Diagnostics Testing Process -- Targeted Mutation Analysis Methods -- Polymerase Chain Reaction -- Real-time Polymerase Chain Reaction -- Reverse-Transcription Polymerase Chain Reaction -- Allele-Specific Polymerase Chain Reaction. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Fragment Analysis -- Sanger Sequencing -- Pyrosequencing -- Methylation Analysis -- Microsatellite Instability Analysis/Assessment of Mismatch Repair Deficiency -- Fluorescence In Situ Hybridization -- Whole-Genome Analysis Methods -- Next-Generation Sequencing -- Genomic Microarrays -- Expression Panels -- Immunohistochemistry for Tumor Biomarkers -- PD-L1 -- ALK and ROS1 -- BRAFV600E -- Cell-Free DNA Technologies -- 3. Hallmarks of Cancer: An Organizing Principle for Cancer Medicine -- Douglas Hanahan and Robert A. Weinberg -- Introduction -- Hallmark Capabilities, In Essence -- Sustaining Proliferative Signaling -- Somatic Mutations Activate Additional Downstream Pathways -- Disruptions of Negative-Feedback Mechanisms that Attenuate Proliferative Signaling -- Excessive Proliferative Signaling Can Trigger Cell Senescence -- Evading Growth Suppressors -- Mechanisms of Contact Inhibition and Its Evasion -- Corruption of the Transforming Growth Factor β Pathway Promotes Malignancy -- Resisting Cell Death -- Autophagy Mediates Both Tumor Cell Survival and Death -- Necrosis Has Proinflammatory and Tumor-Promoting Potential -- Enabling Replicative Immortality -- Reassessing Replicative Senescence -- Delayed Activation of Telomerase May Both Limit and Foster Neoplastic Progression -- Inducing Angiogenesis -- Gradations of the Angiogenic Switch -- Endogenous Angiogenesis Inhibitors Present Natural Barriers to Tumor Angiogenesis -- Pericytes Are Important Components of the Tumor Neovasculature -- A Variety of Bone Marrow-Derived Cells Contribute to Tumor Angiogenesis -- Activating Invasion and Metastasis -- The Epithelial-to-Mesenchymal Transition Program Broadly Regulates Invasion and Metastasis -- Heterotypic Contributions of Stromal Cells to Invasion and Metastasis -- Plasticity in the Invasive Growth Program. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Distinct Forms of Invasion May Underlie Different Cancer Types -- The Daunting Complexity of Metastatic Colonization -- Reprogramming Energy Metabolism -- Evading Immune Destruction -- Two Ubiquitous Characteristics Facilitate the Acquisition of Hallmark Capabilities -- An Enabling Characteristic: Genome Instability and Mutation -- An Enabling Characteristic: Tumor-Promoting Inflammation -- The Constituent Cell Types of the Tumor Microenvironment -- Cancer-Associated Fibroblasts -- Endothelial Cells -- Pericytes -- Immune Inflammatory Cells -- Stem and Progenitor Cells of the Tumor Stroma -- Heterotypic Signaling Orchestrates the Cells of the Tumor Microenvironment -- Coevolution of the Tumor Microenvironment During Carcinogenesis -- Cancer Cells, Cancer Stem Cells, and Intratumoral Heterogeneity -- Therapeutic Targeting of the Hallmarks of Cancer -- Conclusion and a Vision for the Future -- Acknowledgment -- 4. Oncogenic Viruses -- Christopher B. Buck, Lee Ratner, and Giovanna Tosato -- Principles of Tumor Virology -- Papillomaviruses -- History -- Tissue Tropism and Gene Functions -- Human Papillomavirus Vaccines -- Oropharyngeal Cancer -- Nonmelanoma Skin Cancer -- Bladder Cancer -- Polyomaviruses -- History -- BK Polyomavirus -- Merkel Cell Polyomavirus -- Other Human Polyomaviruses -- Epstein-Barr Virus -- History -- Epstein-Barr Virus Life Cycle -- Lymphomas -- Carcinomas -- Prevention and Treatment -- Kaposi Sarcoma Herpesvirus -- History and Epidemiology -- Kaposi Sarcoma-Associated Herpesvirus in Kaposi Sarcoma -- Lymphoproliferative Disorders -- Animal and Human Retroviruses -- Human T-Cell Leukemia Virus Epidemiology -- Human T-Cell Leukemia Virus Molecular Biology -- Clinical Characteristics and Treatment of Human T-lymphotropic Virus 1-Associated Malignancies -- Hepatitis Viruses -- Hepatitis B Virus -- Hepatitis C Virus. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Hepatitis Virus Pathogenesis -- Clinical Characteristics and Treatment of Hepatitis Virus-Associated Malignancies -- Conclusion -- 5. DNA Repair in Normal and Cancer Cells -- Meredith A. Morgan and Theodore S. Lawrence -- Introduction -- Radiation-Induced DNA Damage -- Cellular Responses to Radiation-Induced DNA Damage -- Cell Cycle Checkpoint Pathways -- DNA Repair -- Metabolism -- Innate Immune Response -- Chromosome Aberrations Result from Faulty DNA Double-Strand Break Repair -- Membrane Signaling -- The Effect of Radiation on Cell Survival -- In Vivo Survival Determination of Normal Tissue Response to Radiation -- In Vivo Determination of Tumor Response to Radiation -- Factors That Affect Radiation Response -- The Fundamental Principles of Radiobiology -- Dose-Rate Effects -- Relative Biologic Effectiveness -- Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy -- Cell Cycle -- Tumor Oxygenation -- Immune Response -- Genetic Signatures -- Drugs That Affect Radiation Sensitivity -- Antimetabolites -- Platinums and Temozolomide -- Taxanes -- Molecularly Targeted Agents -- Immunotherapy -- Radiation Protection -- 6. Microbiome and Cancer -- Giorgio Trinchieri -- Introduction -- Cancer as a Disease of the Metaorganism -- Bacteria as Cause of Cancer -- Helicobacter pylori and Stomach Cancer -- Colorectal Cancer -- Tumors in Tissues Not Directly Colonized by the Microbiota -- The Microbiota Modulates Cancer-Predisposing Conditions and Comorbidity -- Bacteria as Cancer Drugs -- Microbiota and Drug Metabolism -- Microbiota and Chemotherapy -- Microbiota and Immunotherapy -- Immune Checkpoint Blockers: Anti-CTLA-4 -- Immune Checkpoint Blockers: Anti-PD-1/PD-L1 -- Looking Forward -- 7. Precision Medicine in Oncology -- James H. Doroshow -- Introduction -- Approach to Precision Medicine in Oncology. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Next-Generation DNA Sequencing for Precision Oncology -- Broadening the Spectrum of Molecular Characterization -- Preclinical Models to Inform Precision Oncology -- Role of Molecular Pharmacodynamics and Diagnostics in Precision Oncology -- Human Biospecimens for Molecular Characterization -- Molecular Pharmacodynamics in Precision Oncology -- Predictive Diagnostic Assays -- Precision Oncology Clinical Trials and Trial Designs -- Imaging and Precision Oncology -- Precision Prevention -- Future Prospects -- 8. Cancer Immunotherapy -- Jeffrey Weber and Iulia Giuroiu -- Introduction -- Interferon-α -- Interleukin-2 -- Talimogene Laherparepvec -- Granulocyte Macrophage Colony-Stimulating Factor -- Tumor-Infiltrating Lymphocytes -- Checkpoint Inhibitors-Cytotoxic T-Lymphocyte Antigen 4 and Programmed Cell Death Protein 1 -- Cytotoxic T-Lymphocyte Antigen 4 Blockade -- Programmed Cell Death Protein 1 and Programmed Cell Death Protein Ligand 1 Blockade -- Melanoma -- Non-small-cell Lung Cancer -- Mismatch-Repair Deficient or Microsatellite Instability-High Cancers -- Renal Cell Carcinoma -- Hodgkin Lymphoma -- Head and Neck Squamous Cell Carcinoma -- Urothelial Carcinoma -- Merkel Cell Carcinoma -- Hepatocellular Carcinoma -- Gastric Cancer -- Cervical Cancer -- Primary Mediastinal Large B-Cell Lymphoma -- Dosing -- Vaccines -- Sipuleucel-T -- Conclusion -- 9. Immunotherapy Agents -- Jeffrey A. Sosman and Douglas B. Johnson -- Introduction -- Human Tumor Antigens -- Mutanome-Associated Neoantigens -- Tumor Vaccines -- Personalized Neoantigen Vaccination -- Immune Checkpoint Inhibitors -- Other Immune Checkpoint Inhibitors in Development -- Anti-TIGIT -- TIM-3 -- LAG-3 -- KIR -- CD73 -- VISTA -- B7-H3 -- Immune Checkpoint Activators -- 4-1BB (CD137) -- GITR -- ICOS -- CD40 -- CD27-CD70 -- OX40 -- Oncolytic Viruses -- Talimogene Laherparepvec. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Other Oncolytic Viruses. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cancer-Genetic aspects. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lawrence, Theodore S. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rosenberg, Steven A. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | DeVita, Vincent T. |
| Title | Cancer: Principles and Practice of Oncology Primer of Molecular Biology in Cancer |
| Place, publisher, and date of publication | Philadelphia : Wolters Kluwer Health,c2020 |
| International Standard Book Number | 9781975149116 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6561640">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6561640</a> |
| Public note | Click to View |
No items available.